Curated News
By: NewsRamp Editorial Staff
May 12, 2026
BioStem Technologies to Present at LD Micro Invitational
TLDR
- BioStem Technologies presents at LD Micro Invitational, gaining investor visibility and potential market edge in regenerative medicine.
- BioStem uses proprietary BioRetain, CryoTek, and SteriTek technologies to preserve perinatal tissue allografts for clinical use.
- BioStem's allograft products help clinicians heal patients, advancing regenerative medicine to improve lives tomorrow.
- BioStem's presentation at the 16th Annual LD Micro Invitational occurs on May 18, 2026, at 1:30 PM ET.
Impact - Why it Matters
This news matters because it signals BioStem Technologies' active engagement with the investment community, potentially increasing visibility and funding for its regenerative medicine products. For patients and healthcare providers, advancements in allograft technologies could lead to better treatment options for tissue repair and regeneration. Investors should watch for updates on BioStem's presentation, which may impact the company's stock and future growth.
Summary
BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company, announced that its management will present at the 16th Annual LD Micro Invitational in Los Angeles, CA. The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET. Interested parties can access live and archived webcasts on the investors section of the company's website at ir.biostemtechnologies.com. This event provides a platform for BioStem to showcase its innovative allograft products and engage with the investment community.
BioStem Technologies is a publicly traded biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies to optimize preservation of natural tissue properties for clinical use. Its allografts are utilized across various medical specialties, and with a growing product portfolio and national commercial footprint, BioStem is advancing innovation in regenerative medicine. The company's quality systems are accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices and Good Manufacturing Processes. BioStem's product lines include Neox®, Clarix®, VENDAJE®, and American Amnion™.
This presentation at the LD Micro Invitational highlights BioStem's commitment to expanding its reach in the regenerative medicine market. The company invites stakeholders to follow its progress via email distribution list, social media on X and LinkedIn, and access the latest news in the company's newsroom at https://tinyurl.com/bsemnewsroom.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, BioStem Technologies to Present at LD Micro Invitational
